{"name":"Scios, Inc.","slug":"scios-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Natrecor (nesiritide)","genericName":"Natrecor (nesiritide)","slug":"natrecor-nesiritide","indication":"Acute decompensated heart failure with dyspnea at rest or with minimal exertion","status":"phase_3"},{"name":"nesiritide, furosemide","genericName":"nesiritide, furosemide","slug":"nesiritide-furosemide","indication":"Acute decompensated heart failure with dyspnea at rest or with minimal exertion","status":"marketed"}]}],"pipeline":[{"name":"Natrecor (nesiritide)","genericName":"Natrecor (nesiritide)","slug":"natrecor-nesiritide","phase":"phase_3","mechanism":"Nesiritide is a recombinant B-type natriuretic peptide that binds to natriuretic peptide receptors to promote vasodilation, reduce cardiac preload and afterload, and increase sodium excretion.","indications":["Acute decompensated heart failure with dyspnea at rest or with minimal exertion"],"catalyst":""},{"name":"nesiritide, furosemide","genericName":"nesiritide, furosemide","slug":"nesiritide-furosemide","phase":"marketed","mechanism":"Nesiritide is a recombinant B-type natriuretic peptide that promotes vasodilation and sodium excretion, while furosemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending loop of Henle.","indications":["Acute decompensated heart failure with dyspnea at rest or with minimal exertion"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxPcEtWQ2trSTY3TmdYYWNOcDFJTkRYN1dOY0NlNTlNSEFuVlhhYXZ4S0pFZWMxaDZCQzhFRUlFTGJTb0RaWGprVTJXMzBZRkhXeUtuWGdHd09yZXp1OUQzRnJpLTZ5VGdXd3VmalRCYVp0cy0xZ215OGhxWGJndjRaVHEwNlUyZU94SGZQaXVwODdHZTktRktteGJFejMzckJRLWlTNEtnZFZPa0llUzRUZEt6LXdNZEJuSkJEZVlCVEh0SWlxenFvVnhmSkQzNEd4NkdraVVva0Q2WGl2VGdSVHBfUndKNUw4aHdfNzM2RElVeC1XZVl4OElvVklsYk5DNDFxSHpyMjRCcUNFSlI4aTNVS01sTnp4T1V1YjJVWDB2T3hBeTY1MXpn?oc=5","date":"2025-07-24","type":"pipeline","source":"businesswire.com","summary":"Thermo Fisher Scientific Increases Accessibility to Research With the Launches of Scios 3 and Talos 12 Electron Microscopes at M&M 2025 Conference - businesswire.com","headline":"Thermo Fisher Scientific Increases Accessibility to Research With the Launches of Scios 3 and Talos 12 Electron Microsco","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPa3FDdTZtMjhCSDVReXdnOG1sVF8xX2U4cHRuUnZTVG1RODhoRW11bzhpWjg5bmE3aEZ0ZTh5U2ZzT1EtTHZzYmJBRUJrQWR0OXY2RzRKcEdXUE4wNUc0UGozY3JNdkdSYjZremNONnR6Q19MTDhjYmJ2aHZXbXV2Z05lVHpkZ2diRmNJ?oc=5","date":"2015-01-14","type":"pipeline","source":"Legacy","summary":"Eugene Step Obituary (2015) - San Diego, CA - The Indianapolis Star - Legacy","headline":"Eugene Step Obituary (2015) - San Diego, CA - The Indianapolis Star","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPMlZIM29PQ2pmbUk3aTFacW0tYVpRUWlxRTJ0RjQwMFhvV2pNTlkwZ3dxYjZXLWkxcE9aakNzVXdYa19FSXl0Wjd3UHRFY05CSHl2c0pnQVNKQUpfVThvVzB3YjhFQmlHTXJqTjAzbXdNOWtlVV9yc2Y0ZUVjeWF0MVB5V2dMUQ?oc=5","date":"2013-11-07","type":"pipeline","source":"Drugwatch.com","summary":"J&J Settles Complaint by Paying $2.2 Billion in Damages - Drugwatch.com","headline":"J&J Settles Complaint by Paying $2.2 Billion in Damages","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNaTd1NmpWNzQ3MDdLQWNiajZoZlBnd2Nmd1pxSXh5NFpqNHlSQk1jN19nWFYtMzVqWUlGXzl5RzJ2ZVA3OXB3akRHMzN0bnpVOExSUEx5SWR0RmZjNk1aY2dadnYxUXJFeFh5MHRCX0dIenZhdVd4U1dGazhfbHlaZUxiUVQwZjdBVjRCRFI2UklpV2tneVE?oc=5","date":"2013-11-04","type":"pipeline","source":"CBS News","summary":"Johnson & Johnson to pay $2.2B in U.S. health care fraud settlement - CBS News","headline":"Johnson & Johnson to pay $2.2B in U.S. health care fraud settlement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNR1NGcTdKbmZtOVdrRm00S2hmbDNBakUyeGh5R0M5alR4NUJSa3VNdzJkY2JSeTBIZURrUVRDenV2V1F1NzdCTWU4N3RCWkVKSHdLX3dUMlpjYkM4VkRaVXpEb3hpdjNqTUFTd0pkTUw1b2lZV3lLNUp1bVgzTkY4XzZTcEtfeXRsYlN2NzdBcXRpSkR5ekE?oc=5","date":"2013-11-04","type":"regulatory","source":"NBC News","summary":"J&J to pay $2.2B to end drug-label and kickback probes - NBC News","headline":"J&J to pay $2.2B to end drug-label and kickback probes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNQUN2WWE5RUxOcHpsc3lYSmotbDd1cnRiZDlINDB6U3lsX0dlWnhnT3YtZ0JUbWYtVnlpM3kwS2FWXzNLSW1LbEpPa1BPZ19vU1FYRlJ6QkNiYUoyMHhSTzFucTdOQmZ3aThlNFB1MllIcmdtaVoxUWNPTkFpR3NtMl9wM2YwZw?oc=5","date":"2007-08-09","type":"pipeline","source":"Mountain View Voice","summary":"Alza Corp. leaving city after 17 years - Mountain View Voice","headline":"Alza Corp. leaving city after 17 years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQeXVsT0hlTFh0R2RQbkpoQm96RW5RTXZyNWlMdDMxRjNtNGtZeFZZWDJGZENoRFZrNU9sR3pJQ2pnZ3N1SENQc01GNzAtNWk3QVRjTjQxZHA1RmcyY0plajVraTBGNjlwMGF1by1MbzB4N29ScHc2bHZpUloyZXJKLXFLVlJmRnB5OU1FeTNvRkNfWkpp?oc=5","date":"2005-08-23","type":"pipeline","source":"Contract Pharma","summary":"Top 20 Pharmaceutical Companies Report - Contract Pharma","headline":"Top 20 Pharmaceutical Companies Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPQnF3TGpzWEpneGNlWHdkTWpaX1gxTi1IWVNVdHhVZE9ITlVrUnBYdldEemhkQW5ILTRiZlQwTXFMMzBJWkdqY1F1amNRNWF6dHdKaXlhTUJCLW1oVzBzMWRhM2pONVZKa1EzajZyczc4TnRVZVFqZjhIWHpWSW84Yy1BTlYzZy1yUFJ2eGZzZ1_SAZYBQVVfeXFMTS1VaFFiZklzNDlUR3g1Wm8tSUY0MWh4UVVqT0NwR2tWZnJKRUlKYks0UE9jTW9XaHhYQm5BWkc2WnFZbGV5TXpRdVlBU0R5RkR6eC1SdVFRMUJVb2dUXzdrWWlOaWFUUnYxcVp1OFZISGlheDZYQWhOY3dsVHRhekMtX0N0TElhS2t2M1ZWVm10bnhrNkFB?oc=5","date":"1992-09-03","type":"pipeline","source":"upi.com","summary":"Scios completes Nova acquisition - upi.com","headline":"Scios completes Nova acquisition","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}